IP Library Granted Patent US 9,499,628
Granted Patent B2
US 9,499,628 · App. 14/304,803 · Granted Nov 22, 2016

Method of boosting the immune response in neonates

Inventor: Sing Sing Way (Cincinnati, OH)
Assignee: Children's Hospital Medical Center
C07K16/2881A61K2039/505
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,628
App. No.
14/304,803
Granted
Nov 22, 2016
Kind
B2
Abstract

In an aspect, a method of augmenting an immune response in a subject in need thereof, comprising identifying the subject, and treating the subject to inhibit the immune suppressive effect of CD71 + cells is provided. Further provided is a method of preventing, treating or ameliorating an infection in a subject, comprising administering to the subject an agent that reduces the level of CD71 + cells in the subject.

Claims (12)

1. A method of augmenting an immune response in a subject in need thereof, comprising:

a) identifying the subject; and

b) administering to the subject an agent that specifically binds to CD71, wherein the agent that specifically binds to CD71 is an anti-CD71 antibody, wherein the subject is a neonate or a newborn, and wherein administration of the anti-CD71 antibody leads to an inhibition of an immune suppressive effect of CD71 + cells.

2. The method of claim 1 , wherein the anti-CD71 antibody is R17217.

3. The method of claim 1 , wherein the anti-CD71 antibody is C2F2.

4. A method of treating or ameliorating an infection in a subject, comprising administering to the subject an agent that reduces the level of CD71 + cells in the subject, wherein the agent specifically binds to CD71, wherein the agent is an anti-CD71 antibody, and wherein the subject is a neonate or a newborn.

5. The method of claim 4 , wherein the anti-CD71 antibody is a humanized antibody.

6. The method of claim 4 , wherein the anti-CD71 antibody is a human antibody.

7. The method of claim 4 , wherein the agent downregulates the level of CD71 + cells.

8. The method of claim 4 , comprising identifying the subject at risk for the infection.

9. The method of claim 1 , wherein the newborn is less than 28 days old.

10. The method of claim 4 , wherein the newborn is less than 28 or days old.

Assignments (3)
CONFIRMATORY LICENSE Recorded Jan 23, 2017
From: CINCINNATI CHILDRENS HOSP MED CTR
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041061/0005 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2015
From: WAY, SING SING
To: CHILDREN'S HOSPITAL MEDICAL CENTER
Reel/Frame 035299/0346 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2014
From: WAY, SING SING
To: CHILDREN'S HOSPITAL MEDICAL CENTER
Reel/Frame 033313/0736 →
Continuity (2)
Provisional Application 61835427 · Jun 14, 2013
Related Publication 20140370004A1 · Dec 18, 2014